Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat ...

PITTSBURGH, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines, today ...

It has been a challenging year for biotech companies that have gone public within the last two years. However, a quick glance at the Nasdaq Biotechnology Index suggests things are much calmer than ...

Operator: Good morning and welcome to the Trinity Biotech Fourth Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be ...

Led by Brett Giroir and GSK’s ex-chief medical officer, Altesa is advancing a medicine that’s changed hands multiple times and once failed a study in asthma.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising ...

The ups and downs of the biotech markets have kept the Fierce Biotech team incredibly busy over the past year. Behind the scenes, we have been working hard to bring you in-depth coverage of the ...

Verona Pharma plc (NASDAQ:VRNA) is a London-based clinical stage biopharmaceutical company, focused on development and commercialization of therapies for the treatment of respiratory diseases with ...

The global biotechnology market is expected to grow at a rate of 13-15% over the next five years. Key drivers of this growth ...

A robot at work inside CMU's Biological and Chemical Innovation Cloud Lab. GIF: Ryan Deto/Axios Pittsburgh's biotech industry is ahead of the curve, according to the National Security Commission on ...